- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04627142
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
A Phase 1 Open-label Dose Escalation Trial of BI 1701963 in Combination With Irinotecan in KRAS Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
This study is open to adults with advanced bowel cancer (colorectal cancer) with a KRAS mutation. This is a study in people for whom previous treatment was not successful and surgery is not a treatment option.
The purpose of this study is to find the highest dose of BI 1701963 that people with bowel cancer can tolerate when taken together with a medicine called irinotecan. The study also tests whether BI 1701963 in combination with irinotecan is able to make tumours shrink. BI 1701963 may help to turn off KRAS. Activating KRAS mutations make tumours grow. Irinotecan is a medicine to treat bowel cancer.
Participants can stay in the study as long as they benefit from treatment and can tolerate it.
During this time, participants take BI 1701963 as tablet once a day and get irinotecan as infusion every two weeks. The doctors regularly monitor the size of the tumour. The doctors also collect information on any health problems of the participants.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200120
- Shanghai East Hospital, Tongji University China
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient must have a confirmed activating KRAS mutation in CRC tumour tissue by local test. Activating mutations include but are not limited to: KRAS mutations in exon 2 (G12, G13), exon 3 (A59, Q61) and exon 4 (K117, A146)
- Patients must have a histological or cytological diagnosis of CRC
- Patients must have received at least first-line chemotherapy (oxaliplatin/ 5-Fluorouracil (5-FU)/ capecitabine et al treatment failure) for unresectable locally advanced or metastatic CRC
- Must have at least one target lesion that can be accurately measured per RECIST version 1.1
- Must have Eastern Cooperative Oncology Group score of 0 or 1
Must show adequate organ function defined as all of the following:
- Absolute neutrophil count (ANC) ≥1.5 x 109/L; haemoglobin ≥9.0 g/dL; platelets ≥100 x 109/L without the use of hematopoietic growth factors within 4 weeks of start of Trial medication.
- Total bilirubin ≤1.5 x Upper Limited of Normal (ULN), or ≤4 x ULN for patients who are known to have Gilbert's syndrome
- Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if concurrent glomerular filtration rate (GFR) ≥30 mL/min (measured or calculated by CKD-EPI formula)
- Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤3 x ULN if no demonstrable liver metastases, or otherwise ≤5 x ULN
- For patients participating in the combination dose escalation and expansion parts (Part B and C), must be eligible to receive treatment with irinotecan in accordance with the local label including Summary of Product Characteristics (SmPC), U.S. PI or Chinese Label
- Must be at least 18 years of age at screening
- Must have recovered from any previous therapy related toxicity to CTCAE grade ≤1 before the first dose (except for alopecia; stable sensory neuropathy must be CTCAE grade ≤2)
- Signed and dated written informed consent in accordance with good clinical practice and local legislation prior to admission to the trial
- further inclusion criteria apply
Exclusion Criteria:
- Previous anticancer chemotherapy, anticancer immunotherapy, and/or other anticancer biologic therapy within 3 weeks of the first administration of trial drug. Previous anticancer hormonal therapy within 2 weeks of first administration of trial drug
- Previous treatment with a RAS, Mitogen-activated protein kinase (MAPK) or Son of Sevenless 1 (SOS1) targeting agent
- For patients participating in the combination dose escalation and expansion parts (Part B and C only): Previous treatment with irinotecan
Radiotherapy within 4 weeks except as follows
- Palliative radiotherapy to regions other than the chest is allowed up to 2 weeks prior to start of treatment
- Single dose palliative radiotherapy for symptomatic metastasis within 2 weeks prior to start of treatment may be allowed but must be discussed with the sponsor
- Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the trial, e.g. hip replacement
- Previous treatment with any investigational agent(s) or targeted treatment within 28 days prior to start of treatment
- Known history of hypersensitivity to any of the excipients of BI 1701963 tablets
- History or presence of cardiovascular abnormalities such as uncontrolled Hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥3, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator; Myocardial infarction within 6 months prior to start of treatment
- Left ventricular ejection fraction (LVEF) <50%
- Congenital long QT prolongation syndrome or mean resting corrected QT interval (QTcF) >470 msec
- further exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Expansion dose 1
Part C: Combination therapy expansion part
|
Tablet
Solution for infusion
|
Experimental: Expansion dose 2
Part C: Combination therapy expansion part
|
Tablet
Solution for infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD) based on the number of dose limiting toxicities (DLTs) in the MTD evaluation period
Time Frame: 28 days
|
Combination dose escalation part (Part B)
|
28 days
|
Number of patients experiencing DLTs in the MTD evaluation period
Time Frame: 28 days
|
Combination dose escalation part (Part B)
|
28 days
|
Objective Response (OR) according to RECIST version 1.1
Time Frame: 28 days per treatment cycle.
|
Combination therapy expansion part (Part C)
|
28 days per treatment cycle.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with DLTs in the first treatment cycle
Time Frame: 28 days
|
Monotherapy safety run-in part (Part A)
|
28 days
|
Maximum measured concentration of BI 1701963 in plasma (Cmax)
Time Frame: 28 days per treatment cycle.
|
Monotherapy safety run-in part (Part A)
|
28 days per treatment cycle.
|
Area under the concentration time curve of BI 1701963 in plasma over the time interval from 0 to the last quantifiable plasma concentration (AUC0-tz)
Time Frame: 28 days per treatment cycle.
|
Monotherapy safety run-in part (Part A)
|
28 days per treatment cycle.
|
Area under the concentration-time curve of BI 1701963 in plasma over the dosing interval τ at steady state (AUCτ(,ss))
Time Frame: 28 days per treatment cycle.
|
Monotherapy safety run-in and combination dose escalation part (Part A+B)
|
28 days per treatment cycle.
|
Maximum measured concentration of BI 1701963 in plasma at steady state over a uniform dosing interval tau (Cmax,ss)
Time Frame: 28 days per treatment cycle.
|
Monotherapy safety run-in and combination dose escalation part (Part A+B)
|
28 days per treatment cycle.
|
Duration of objective response (DOR)
Time Frame: 28 days per treatment cycle.
|
Combination therapy expansion part (Part C)
|
28 days per treatment cycle.
|
Tumour shrinkage (in millimetres)
Time Frame: 28 days per treatment cycle.
|
Combination therapy expansion part (Part C)
|
28 days per treatment cycle.
|
Progression-free survival (PFS)
Time Frame: Up to 6 months.
|
Combination therapy expansion part (Part C)
|
Up to 6 months.
|
Number of patients experiencing grade ≥3 treatment-related AEs during the entire treatment period
Time Frame: 28 days per treatment cycle.
|
Combination therapy expansion part (Part C)
|
28 days per treatment cycle.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Irinotecan
Other Study ID Numbers
- 1432-0008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
For more details refer to: https://www.mystudywindow.com/msw/datasharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer (CRC)
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Zhejiang Teruisi Pharmaceutical Inc.Not yet recruitingMetastatic Colorectal Cancer (CRC)
-
Cardiff OncologyPfizerRecruitingMetastatic Colorectal Cancer | CRC | KRAS/NRAS MutationUnited States
-
University of California, IrvineActive, not recruitingColorectal Cancer | Metastatic Cancer | Colorectal Carcinoma | CRCUnited States
-
Beijing Biostar Pharmaceuticals Co., Ltd.Chengdu Biostar PharmaceuticalsSuspendedAdvanced or Metastatic CRCChina
-
Inspirna, Inc.RecruitingGastrointestinal Neoplasms | Colorectal Neoplasms | Gastric Cancer | Colorectal Cancer | Colorectal Cancer Metastatic | Gastrointestinal Cancer | Colorectal Carcinoma | CRC | KRAS Mutation-Related Tumors | Gastric NeoplasmUnited States
-
LetolabNot yet recruitingLocally Advanced or Metastatic CRC
-
Incyte CorporationTerminatedCRC (Colorectal Cancer)United States, France, United Kingdom, Spain, Israel, Australia, Germany, Korea, Democratic People's Republic of
-
Bristol-Myers SquibbCompletedColorectal Cancer (CRC)United States, Argentina, Italy
-
Chinese University of Hong KongNot yet recruitingCRC, Colorectal CancerHong Kong
Clinical Trials on BI 1701963
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimActive, not recruitingSolid Tumors, KRAS Mutation; SOS1United States, Netherlands, Germany
-
Mirati Therapeutics Inc.Boehringer IngelheimCompletedMetastatic Cancer | Advanced Cancer | Malignant Neoplasm of Colon | Malignant Neoplasm of Lung | Malignant Neoplastic DiseaseUnited States
-
Boehringer IngelheimActive, not recruitingSolid Tumors, KRAS MutationSpain, United Kingdom, United States, Belgium
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimRecruitingMelanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)Netherlands
-
Boehringer IngelheimNot yet recruiting
-
Boehringer IngelheimWithdrawnAnal Canal Squamous Cell CarcinomaKorea, Republic of
-
Boehringer IngelheimRecruiting